Best Options Strategy for ZNTL
Looking for the best options strategy for Zentalis Pharmaceuticals, Inc. (ZNTL)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live ZNTL option chain right now, and a simple map from your view on ZNTL to the strategy that fits it. Model any of them in the calculator before you trade.
About ZNTL
Zentalis Pharmaceuticals, Inc. (ZNTL) is a major company in Biotechnology. Options traders on ZNTL tend to watch , since these can drive large moves in the share price.
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals is a clinical-stage biotech company headquartered in San Diego that develops small-molecule cancer drugs. Its lead candidate, azenosertib, is being tested in a Phase 3 trial for ovarian cancer and other solid tumors. The company also operates earlier-stage studies examining azenosertib as a monotherapy in various cancers and in combination approaches for patients whose tumors have become resistant to PARP inhibitors. The firm maintains licensing arrangements and collaborative relationships with external partners, including Recurium IP Holdings, to support its research and development efforts.
Since Zentalis remains in clinical development stages rather than commercializing approved medicines, it generates minimal product revenue. The company's financial model depends on funding from investors, grants, and potentially milestone payments tied to clinical progress from its licensing partners. Its market presence is limited to the research and development sphere, without yet competing in the commercial oncology marketplace. The company's value proposition centers on the potential clinical utility of its drug candidates and the intellectual property…
Today's top-scoring strategy for ZNTL
Our engine ranks defined-risk strategies on the live ZNTL chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | CALL | $95 | $6.83 |
| Sell | 2× | CALL | $100 | $3.82 |
| Buy | 1× | CALL | $105 | $1.87 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Illustrative example at ZNTL's latest available price, computed with the same engine as the tool. Live option fills and the real IV skew refresh during US market hours.
Implied volatility
ZNTL typically trades with moderate implied volatility, broadly in line with other large-cap stocks. Implied volatility drives option prices, so it is worth checking the live chain before you trade.
Earnings & IV crush
ZNTL's next earnings report is due around August 6, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
Key figures
- Market cap
- $317M
- Beta (vs market)
- 1.98
- 52-week range
- $1.15–$6.95
- Short interest
- 8.8% of float · 5.3 days to cover
How to choose an options strategy for ZNTL
Start with your outlook on ZNTL, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while ZNTL stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open ZNTL in the free calculator →
Frequently asked questions
What is the best options strategy for ZNTL?
It depends on your outlook. Bullish traders often use a long call or bull call spread on ZNTL; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are ZNTL options liquid enough to trade?
Zentalis Pharmaceuticals, Inc. (ZNTL) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade ZNTL options?
Buying a single ZNTL call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade ZNTL or any security. Do your own research.
What does Zentalis Pharmaceuticals, Inc. do?
Zentalis Pharmaceuticals, Inc. (ZNTL) operates in the Biotechnology industry. The "About Zentalis Pharmaceuticals, Inc." section above gives a fuller picture of what the company does and how it earns money.
Does Zentalis Pharmaceuticals, Inc. pay a dividend?
Zentalis Pharmaceuticals, Inc. does not currently pay a dividend, so there is no ex-dividend assignment risk to plan around for options strategies.
When does Zentalis Pharmaceuticals, Inc. next report earnings?
Zentalis Pharmaceuticals, Inc.'s next earnings are expected around August 6, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.
Tickers related to ZNTL
Comparing ZNTL with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 10275 Science Center Dr., Suite 200, San Diego, CA, 92121, United States
- Industry
- Biotechnology
- Employees
- 106
- CEO
- Ms. Julie M. Eastland M.B.A.
- Phone
- 858 263 4333
- Website
- zentalis.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.